Literature DB >> 22555167

Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART.

David H Adler1, Lisa Kakinami, Tebogo Modisenyane, Nkeko Tshabangu, Lerato Mohapi, Guy De Bruyn, Neil A Martinson, Tanvier Omar.   

Abstract

OBJECTIVE: To determine the impact of HAART on incidence, regression, and progression of cytopathological abnormalities in HIV-infected women.
DESIGN: Prospective cohort.
METHODS: HIV-infected women (N=1123) from Soweto, South Africa underwent serial cervical smears that were analyzed and reported using the Bethesda System. The results of HAART and non-HAART users were compared using two statistical approaches: a survival analysis assessing risk of incident smear abnormality among women with baseline normal smear results; and analysis with marginal models assessing for an association between HAART use and likelihood of regression/progression in consecutive smears.
RESULTS: After multivariate survival analysis, women using HAART with a normal baseline smear were 38% less likely to have an incident smear abnormality during follow-up than nonusers [confidence interval (CI) 0.42-0.91; P=0.01]. Multivariate marginal models analysis identified a significantly increased likelihood (odds ratio 2.61; CI 1.75-3.89; P<0.0001) of regression of cervical lesions among women on HAART.
CONCLUSION: Our large prospective cohort study adds significant weight to the side of the balance of clinical research supporting the positive impact of HAART on the natural history of human papillomavirus-related cervical disease in HIV-infected women.
© 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Year:  2012        PMID: 22555167      PMCID: PMC3709565          DOI: 10.1097/QAD.0b013e32835536a3

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost.

Authors:  Binh H Yang; Freddie I Bray; D Maxwell Parkin; John W Sellors; Zuo-Feng Zhang
Journal:  Int J Cancer       Date:  2004-04-10       Impact factor: 7.396

Review 2.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

3.  The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women.

Authors:  H Minkoff; L Ahdieh; L S Massad; K Anastos; D H Watts; S Melnick; L Muderspach; R Burk; J Palefsky
Journal:  AIDS       Date:  2001-11-09       Impact factor: 4.177

Review 4.  The 2001 Bethesda System: terminology for reporting results of cervical cytology.

Authors:  Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young
Journal:  JAMA       Date:  2002-04-24       Impact factor: 56.272

5.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

6.  High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil.

Authors:  José E Levi; Bernhard Kleter; Wim G V Quint; Maria C S Fink; Cynthia L M Canto; Regina Matsubara; Iara Linhares; Aluísio Segurado; Bart Vanderborght; José Eluf Neto; Leen-Jan Van Doorn
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

7.  Presence of multiple human papillomavirus types in cervical samples from HIV-infected women.

Authors:  José Eduardo Levi; Silvana Fernandes; Adriana Fumie Tateno; Eduardo Motta; Liliam Pereira Lima; José Eluf-Neto; Cláudio Sérgio Pannuti
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

8.  Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.

Authors:  Paula Schuman; Suzanne E Ohmit; Robert S Klein; Ann Duerr; Susan Cu-Uvin; Denise J Jamieson; Jean Anderson; Keerti V Shah
Journal:  J Infect Dis       Date:  2003-06-17       Impact factor: 5.226

9.  Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women.

Authors:  Isabelle Heard; Jean-Michel Tassie; Michel D Kazatchkine; Gérard Orth
Journal:  AIDS       Date:  2002-09-06       Impact factor: 4.177

10.  Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women.

Authors:  Annarosa Del Mistro; Roberta Bertorelle; Marzia Franzetti; Annamaria Cattelan; Angela Torrisi; Maria Teresa Giordani; Roberto Sposetti; Emanuela Bonoldi; Lolita Sasset; Laura Bonaldi; Daria Minucci; Luigi Chieco-Bianchi
Journal:  Clin Infect Dis       Date:  2004-02-18       Impact factor: 9.079

View more
  31 in total

1.  Oral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women.

Authors:  Cecile D Lahiri; Katherine B Dugan; Xianhong Xie; Laura Reimers; Robert D Burk; Kathryn Anastos; Leslie Stewart Massad; Isam-Eldin Eltoum; Xiaonan Xue; Gypsyamber DʼSouza; Lisa Flowers; Joel M Palefsky; Lisa Rahangdale; Howard D Strickler; Ighovwerha Ofotokun
Journal:  J Acquir Immune Defic Syndr       Date:  2015-10-01       Impact factor: 3.731

2.  Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.

Authors:  Adriana Weinberg; Sharon Huang; Anna-Barbara Moscicki; Afred Saah; Myron J Levin
Journal:  AIDS       Date:  2018-04-24       Impact factor: 4.177

3.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

4.  Risk factors for cervical precancer detection among previously unscreened HIV-infected women in Western Kenya.

Authors:  Megan J Huchko; Hannah Leslie; Jennifer Sneden; May Maloba; Naila Abdulrahim; Elizabeth A Bukusi; Craig R Cohen
Journal:  Int J Cancer       Date:  2013-09-13       Impact factor: 7.396

Review 5.  Oral human papillomavirus infection and head and neck cancers in HIV-infected individuals.

Authors:  Daniel C Beachler; Gypsyamber DʼSouza
Journal:  Curr Opin Oncol       Date:  2013-09       Impact factor: 3.645

6.  Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.

Authors:  Myron J Levin; Sharon Huang; Anna-Barbara Moscicki; Lin-Ye Song; Jennifer S Read; William A Meyer; Alfred J Saah; Kelly Richardson; Adriana Weinberg
Journal:  Vaccine       Date:  2017-02-24       Impact factor: 3.641

Review 7.  Incidence and progression of cervical lesions in women with HIV: a systematic global review.

Authors:  Sheri A Denslow; Anne F Rositch; Cynthia Firnhaber; Jie Ting; Jennifer S Smith
Journal:  Int J STD AIDS       Date:  2013-08-29       Impact factor: 1.359

8.  Outcomes Up to 12 Months After Treatment With Loop Electrosurgical Excision Procedure for Cervical Intraepithelial Neoplasia Among HIV-Infected Women.

Authors:  Megan J Huchko; Hannah Leslie; May Maloba; Jennifer Zakaras; Elizabeth Bukusi; Craig R Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

Review 9.  Cancer prevention in HIV-infected populations.

Authors:  Priscila H Goncalves; Jairo M Montezuma-Rusca; Robert Yarchoan; Thomas S Uldrick
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

10.  Factors associated with recurrence of cervical intraepithelial neoplasia 2+ after treatment among HIV-infected women in Western Kenya.

Authors:  Megan J Huchko; Hannah Leslie; May Maloba; Elizabeth A Bukusi; Craig R Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.